CPC A61K 38/179 (2013.01) [A61K 9/0048 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61P 27/02 (2018.01)] | 38 Claims |
1. A method for treating an angiogenic eye disorder in a human subject in need thereof comprising administering, intravitreally into an eye of the subject, in a volume of about 100 microliters or less, at least about 8 mg of a VEGF receptor fusion protein comprising two polypeptides that comprise an immunoglobulin-like (Ig) domain 2 of VEGFR1, an Ig domain 3 of a VEGFR2, and a multimerizing component; wherein the VEGF receptor fusion protein is in an aqueous pharmaceutical formulation comprising at least 100 mg/ml of the VEGF receptor fusion protein and having a viscosity of about 5-15 centiPoise (cP) at 20° C.
|